ASCO presentations in late May 2026 could catalyze upward stock movement, especially if Olverembatinib or Lisaftoclax show strong Phase III data. Monitor for safety/efficacy signals in key trials, particularly the POLARIS-2 and GLORA studies, which are pivotal for U.S. regulatory approval. Positive data may re-rate the stock given the company's $2.3B market cap.
Price Chart
Executive Summary
Ascentage Pharma announced that six clinical study abstracts for its key drug candidates—Olverembatinib, Lisaftoclax, and Alrizomadlin—have been accepted for presentation at the 2026 ASCO Annual Meeting, including three rapid oral presentations. This marks the company's ninth consecutive year presenting at ASCO, highlighting ongoing clinical momentum and global recognition of its R&D pipeline. While no new clinical data is released yet, the inclusion of multiple late-stage trials underscores the potential of its oncology portfolio.
Key Facts
- Six abstracts from Ascentage Pharma's clinical programs accepted for ASCO 2026, including three rapid oral presentations.
- Drugs featured: Olverembatinib (HQP1351), Lisaftoclax (APG-2575), and Alrizomadlin (APG-115), all under investigation in the U.S.
- Key trials highlighted: POLARIS-2 (Phase III for Olverembatinib in CML), GLORA (Phase III for Lisaftoclax in CLL/SLL), and pediatric sarcoma study with APG-115.
- This is Ascentage Pharma’s ninth straight year presenting at ASCO, reinforcing its R&D credibility in oncology.
Financial Impact
Non-dilutive, near-term value inflection expected from upcoming data readouts at ASCO 2026.
Risk Factors
- Clinical data to be presented may not meet expectations, leading to downside volatility.
- None of the drugs have FDA approval yet; regulatory risk remains high for U.S. submissions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.85 (−3.82%) |
Oct 21, 2026 6d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.85 (−0.47%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.85 (+1.09%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.85 (+3.38%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.85 (+14.26%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.85 (−11.90%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.85 (−11.63%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.85 (−21.39%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.85 (−19.16%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.85 (−22.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers